L3VLUP
ProSign in

CYTK · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

CYTKLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • CYTK
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterCYTKLLY
Q3 20205 holders, $114m33 holders, $14.1bn
Q4 20203 holders, $90m29 holders, $17.3bn
Q1 20213 holders, $90m24 holders, $23.0bn
Q2 20212 holders, $74m24 holders, $27.8bn
Q3 20217 holders, $643m31 holders, $29.9bn
Q4 202110 holders, $794m31 holders, $34.7bn
Q1 20226 holders, $624m24 holders, $35.3bn
Q2 202210 holders, $1.0bn33 holders, $42.7bn
Q3 20229 holders, $1.0bn31 holders, $43.4bn
Q4 202212 holders, $1.1bn31 holders, $46.6bn
Q1 202311 holders, $895m33 holders, $44.3bn
Q2 20238 holders, $781m37 holders, $59.6bn
Q3 202310 holders, $753m44 holders, $67.6bn
Q4 202312 holders, $2.4bn45 holders, $73.6bn
Q1 202415 holders, $1.8bn41 holders, $95.3bn
Q2 202416 holders, $1.5bn43 holders, $110bn
Q3 202415 holders, $1.5bn45 holders, $107bn
Q4 202411 holders, $1.1bn46 holders, $93.9bn
Q1 20259 holders, $544m42 holders, $98.4bn
Q2 20254 holders, $268m43 holders, $93.2bn
Q3 20256 holders, $1.3bn39 holders, $86.7bn
Q4 20258 holders, $1.5bn41 holders, $123bn
Q1 202611 holders, $1.5bn39 holders, $106bn
Q2 202612 holders, $1.3bn44 holders, $132bn
CYTK

Cytokinetics Inc

Holders
15
Reported value
$1.8bn
Buyers
10
Sellers
5

Breadth +5 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
41
Reported value
$95.3bn
Buyers
15
Sellers
27

Breadth -12 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 46 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only CYTK (5)

Brevan Howard Capital Management LP, Davidson Kempner Capital Management LP, Farallon Capital Management LLC, Hudson Bay Capital Management LP, Voloridge Investment Management LLC

Only LLY (31)

Acadian Asset Management LLC, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, GAMCO Investors Inc, Holocene Advisors LP, Invesco Ltd, Jane Street Group LLC, Man Group PLC, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Polen Capital Management LLC, Renaissance Technologies LLC, Rokos Capital Management LLP, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, and 6 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →